Abstract: Provided are a non-woven cloth and a layered non-woven cloth that are preferred as a skin material for a composite sound-absorbing material, which has excellent moldability and exceptional shape stability, and with which it is possible to achieve an adequate sound-absorption effect even in thin low-weight regions.

Abstract: Provided is a composite sound-absorbing material that can exhibit sound absorption properties in a broad range of low frequencies, intermediate frequencies, and high frequencies even in a low-basis-weight region having low thickness. The composite sound-absorbing material according to the present invention is configured from two or more layers including a base material and a skin material, the skin material being positioned on the outermost layer, wherein the composite sound-absorbing material is characterized in that the ratio (skin material:base material) of the surface area (m2/m2) per unit area of the skin material and the surface area (m2/m2) per unit area of the base material is at least 1:5 and less than 1:40.

Abstract: The information processing device includes an information storage unit, a data acquisition unit, and a user characteristic score calculation unit. The information storage unit stores information regarding the user and information regarding the actions of other users. The data acquisition unit acquires information regarding the characteristic item from the information storage unit. The user characteristic score calculation unit includes a self-evaluation score calculation unit, an other-evaluation score calculation unit, and a final evaluation score calculation unit. The self-evaluation score calculation unit calculates a self-evaluation score by the user. The other-evaluation score calculation unit calculates the other-person evaluation score by other users. The final evaluation score calculation unit calculates the user evaluation score based on the weighting coefficient, the self-evaluation score, and the other-person evaluation score.

Abstract: Provided is a program in which any of a plurality of stage-raising conditions different from each other is set for any stage, the program causing a computer to execute steps of: determining, upon acceptance of a player input for selecting a target game medium from among a game medium (or media), the stage of the target game medium being to be raised, whether a first stage-raising condition set for the stage of the target game medium is satisfied; determining whether a stage-raising condition set for the next stage thereof is a second stage-raising condition, in the case where it is determined that the first stage-raising condition is satisfied; and displaying a transition-instruction accepting unit for making the transition to a screen for presenting the second stage-raising condition, in the case where it is determined that the stage-raising condition set for the next stage is the second stage-raising condition.

Abstract: Provided is an information processing program for causing a computer to realize: a joint-event generation management unit that consumes a first parameter and generates a joint event; a number-of-players determination unit that determines an upper-limit number of players allowed to participate in the joint event; a joint-event participation management unit that consumes a second parameter and that permits other players to participate in the joint event; a privilege management unit that grants an execution privilege for the joint event to a player; a joint-event execution control unit that starts the execution of the joint event when replies have been accepted from all the players except the player who has been granted the execution privilege; a reward providing unit that provides a reward to each player; and a joint-event number-of-times checking unit that checks whether the number of times for execution of the joint event has reached the upper-limit number.

Abstract: Provided is an information processing program for causing a computer to realize: a joint-event generation management unit that consumes a first parameter and generates a joint event; a number-of-players determination unit that determines an upper-limit number of players allowed to participate in the joint event; a joint-event participation management unit that consumes a second parameter and that permits other players to participate in the joint event; a privilege management unit that grants an execution privilege for the joint event to a player; a joint-event execution control unit that starts the execution of the joint event when replies have been accepted from all the players except the player who has been granted the execution privilege; a reward providing unit that provides a reward to each player; and a joint-event number-of-times checking unit that checks whether the number of times for execution of the joint event has reached the upper-limit number.

Abstract: In one embodiment, a method of manufacturing a magnetic disk includes rotating a magnetic disk, supporting a floating head on the rotating magnetic disk, the floating head having a slider body and an element unit formed on a trailing edge of the slider body, contacting a floating surface of the slider body with the magnetic disk, and protruding a portion of the floating head toward the magnetic disk due to application of power to a heater element within the element unit, wherein the element unit is positioned away from the magnetic disk. In another embodiment, a floating head includes a slider body comprising AlTiC, an element unit positioned on a trailing edge of the slider body, the element unit having an initial recess amount of at least about 4 nm, and a heater element positioned within an alumina protective film of the element unit.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: In one embodiment, a method of manufacturing a magnetic disk includes rotating a magnetic disk, supporting a floating head on the rotating magnetic disk, the floating head having a slider body and an element unit formed on a trailing edge of the slider body, contacting a floating surface of the slider body with the magnetic disk, and protruding a portion of the floating head toward the magnetic disk due to application of power to a heater element within the element unit, wherein the element unit is positioned away from the magnetic disk. In another embodiment, a floating head includes a slider body comprising AlTiC, an element unit positioned on a trailing edge of the slider body, the element unit having an initial recess amount of at least about 4 nm, and a heater element positioned within an alumina protective film of the element unit.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: Phenylalanine derivatives of the following formula, analogues thereof and pharmaceutically acceptable salts thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents or preventive agents for various diseases concerning ?4 integrin in which ?4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection. wherein R1 is a methyl group and R2 is a methoxy group.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the ? 4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which ? 4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

Abstract: A programmable controller has a first (executing) CPU unit and a second (standby) CPU unit for a duplexed operation. Each CPU unit stores CPU version indicating its functionality and function version indicative of the functionality of the user program stored in itself. Before the duplexed operation is started, the first CPU unit acquires the unit version of the second CPU unit, compares it with the function version stored in itself and judges from this comparison whether a duplexed operation is possible or not. Only if it is judged that the duplexed operation is possible, the first CPU unit copies the user program stored in itself to the second CPU unit together with the function version and the duplexed operation is started.

Abstract: Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the ?4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which ?4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

Abstract: Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the ? 4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which ? 4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

Abstract: Phenylalanine derivatives of the following formula, analogues thereof and pharmaceutically acceptable salts thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents or preventive agents for various diseases concerning ?4 integrin in which ?4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection. wherein R1 is a methyl group and R2 is a methoxy group.

Abstract: The present invention provides novel benzene compounds presented by the following formulas, and analogs thereof, that exert an ACC activity-inhibiting effect that is effective in the treatment of obesity, hyperlipemia, fatty liver, hyperglycemia, impaired glucose tolerance, diabetes, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, and diabetic macroangiopathy, hypertension, arteriosclerosis), hypertension, and arteriosclerosis.